7 articles for “toxicity trials”

Set a search alert

Research ArticleOpen accessPhrase in the titleBoric Acid Toxicity Trials on the Wood Borer Heterobostrychus aequalis Waterhouse (Coleoptera: Bostrychidae)Daljit Karam Singh, Faizah Abood, Hazandy Abdul-Hamid et al.Abstract: Problem statement: The Heterobostrychus aequalis Waterhouse was a serious pest lumber of timber heveawood. The H. aequalis infest and tunnel along the wood grain, depositing eggs, which concomitantly turn into larvae and reduces the wood starch to a soft powder. The objectives of the study were to establish a suitable method for preservative trials on the wood borer and … …American Journal of Agricultural and Biological Sciences, Vol. 6, Issue 1 · 15 Dec 2010 · 10,231 accessesView PDF Cite

Research ArticleOpen accessIn the keywordsA Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical TrialsMourad Tighiouart, Quanlin Li, Steven Piantadosi, Andre RogatkoWe describe a Bayesian adaptive design for early phase cancer trials of a combination of three agents. This is an extension of an earlier work by the authors by allowing all three agents to vary during the trial and by assigning different drug combinations to cohorts of three patients. The primary objective is to estimate the Maximum Tolerated Dose (MTD) … …Current Research in Biostatistics, Vol. 6, Issue 1 · 25 Aug 2016 · 8,421 accessesView PDF Cite

Research ArticleOpen accessIn the abstractThe 100-Days Oral Toxicity of Tomato Pomace in Healthy MiceWathita Phachonpai, Supaporn Muchimapura, Jintanaporn Wattanathorn et al.Problem statement: Growing attention is being paid to functional food. The beneficial effect of functional food appears to relate to its bioactive ingredient such as substances containing antioxidant. Therefore, the information about the toxicity of the substances is very much essential to recommend the safety for the substances implication in both clinical and application trials. Herein, we have investigated for … …American Journal of Pharmacology and Toxicology, Vol. 7, Issue 1 · 23 May 2012 · 7,601 accessesView PDF Cite

Research ArticleOpen accessIn the abstractCytokines as Adjuvants for Vaccine and Cellular Therapies for CancerChristian M. Capitini, Terry J. Fry, Crystal L. MackallProblem statement: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. Approach: The gamma (γ) family of cytokines offered a unique opportunity to support the … …American Journal of Immunology, Vol. 5, Issue 3 · 30 Sep 2009 · 14,348 accessesView PDF Cite

Research ArticleOpen accessIn the abstractSensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het DrugJohnny Hyde, Doris M. BenbrookThe administration and combination of a variety of chemotherapeutic agents for treatment of advanced or recurrent uterine cancer of different histologies is under current debate. Mixed Mullerian Tumors (MMTs), which contain both adenocarcinoma and sarcoma components, are the most rate histologic type and it is therefore difficult to conduct clinical trials to determine if they should be treated like endometrial … …American Journal of Pharmacology and Toxicology, Vol. 1, Issue 4 · 31 Dec 2006 · 7,460 accessesView PDF Cite

Research ArticleOpen accessAll words, across the recordATLCEP: A New Integrated Design that Encompasses the Safety and Efficacy Objectives of Phase I/II TrialsRevathi Ananthakrishnan, Stephanie Green, Mark Chang et al.Several designs, such as designs to find the optimal biological dose, the Eff-Tox design and seamless Phase I/II designs, have been proposed to evaluate both drug toxicity and efficacy as alternatives to the traditional paradigm of a stepwise drug development approach. Here, we first examine the effect of sample and cohort size on the accuracy of dose selection in early … …Current Research in Biostatistics, Vol. 7, Issue 2 · 7 Apr 2018 · 7,980 accessesView PDF Cite

Research ArticleOpen accessAll words, across the recordConcentration-Effect, Incidence and Mechanism of Nevirapine HepatotoxicityAdikwu Elias, Brambaifa NelsonNevirapine is a dipyridozepinone non nucleoside reverse transcriptase inhibitor approved for use in HIV-infected patients. Its efficacy has been well demonstrated in numerous clinical trials. It has activity against HIV-1 but does not have significant activity against HIV-2 or other retroviruses. Nevirapine is used as one of the components of highly active antiretroviral therapy in HIV patients and in the … …American Journal of Pharmacology and Toxicology, Vol. 8, Issue 1 · 19 Apr 2013 · 8,156 accessesView PDF Cite